This content is only available within our institutional offering.
04 Aug 2017
PANMURE: Traumakine trial continues; recruitment expected to complete Q4
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
PANMURE: Traumakine trial continues; recruitment expected to complete Q4
Faron Pharmaceuticals Oy (FARN:LON) | 190 19 5.7% | Mkt Cap: 215.8m
- Published:
04 Aug 2017 -
Author:
Julie Simmonds -
Pages:
4 -